Laboratory characteristics of a cohort of patients with early rheumatoid arthritis

Revista Brasileira de Reumatologia

Volumn 50, Issue 4, 2010, Pages 381-388

  da Mota, Licia Maria Henrique ^a   dos Neto, Leopoldo Luiz Santos ^b   Burlingame, Rufus ^c   Ménard, Henri A ^d   Laurindo, Ieda Maria Magalhäes ^e  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b HOSPITAL UNIVERSITÁRIO DE BRASÍLIA   (Brazil)

^c INOVA DIAGNOSTICS INC   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anti ccp; Anti sa; Brazilian population; Cohort; Early arthritis; Early rheumatoid arthritis; Rf

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTEIN ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; VIMENTIN CITRULLINATED ANTIBODY;

ADULT; AGED; ANEMIA; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EARLY DIAGNOSIS; ERYTHROCYTE COUNT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; BLOOD; IMMUNOLOGY; MIDDLE AGED;

ADULT; AGED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 77957240743     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358:903-911.
2. Callegari-Jacques SM, Grattapaglia D, Salzano FM, Salamoni SP, Cronetti SG, Ferreira ME et al. Historical genetics: spatiotemporal analysis of the formation of the Brazilian population. Am J Hum Biol 2003; 15:824-834.
3. Lisker R, Ramirez E, Briceno RP. Gene frequencies and admixture estimates in four Mexican urban centers. Hum Biol 1990; 62:791-801.
4. Sans M, Salzano FM, Chakraborty R. Historical genetics in Uruguay: estimates of biological origins and their problems. Hum Biol 1997; 69:161-170.
5. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-324.
6. Boire G, Cossette P, de Brum-Fernandes AJ, Liang P, Niyonsenga T, Zhou ZJ et al. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 2005; 7:R592-603.
7. Cardiel MH; Latin American Rheumatology Associations of the Pan-American League of Associations for Rheumatology (PANLAR); Grupo Latinoamericano de Estudio de Artritis Reumatoide (GLADAR). First Latin American position paper on the pharmacological treatment of rheumatoid arthritis. Rheumatology (Oxford) 2006; 45:27-222.
8. Mijiyawa M. Epidemiology and semiology of rheumatoid arthritis in Third World countries. Rev Rhum Engl Ed 1995; 62:121-126.
9. Grupo Latino Americano de Estudio de Artritis Reumatoide. Disponível em . Acesso em: 07 abr. 2009.
10. Rheumatoid arthritis in Latin America. Disponível em . Acesso em: 27. abr. 2009.
11. Estel BAP, Massardo L, Wojdyla D, Acevedo E, Laurindo IMM, Guibert ZM et al. Is there something we can learn from rheumatoid arthritis in Latin America? A descriptive report on an inception Cohort of 1093 patients Ann Rheum Dis 2008; 67:336 (Abstract).
12. Dixey J, Solymossy C, Young A. Early RA Study, Is it possible to predict radiological damage in early rheumatoid arthritis (RA)? A report on the occurrence, progression, and prognostic factors of radiological erosions over the first 3 years in 866 patients from the Early RA Study (ERAS). J Rheumatol Suppl 2004; 69:48-54.
13. James D, Young A, Kulinskaya E, Knight E, Tomson W, Oliver W et al. Orthopaedic intervention on early rheumatoid arthritis. Occurrences and predictive factors in an inception cohort of 1064 patients followed for 5 years. Rheumatology 2004; 43:369-376.
14. Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21:907-927.
15. Nikolaisen C, Figenschau Y, Nossent JC. Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. J Rheumatol 2008; 35:380-386.
16. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rhematoid arthritis early. A prediction model for persistent (erosive) arthritis, Arthritis Rheum 2002; 46:357-365.
17. Green M, Marzo-Ortega H, McGonagle D, Wakefield R, Proudman S, Conaghan P et al. Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis Rheum 1999; 42:2184-2188.
18. van der Heijde DM, van RP, van RM, van de Putte LB. Influence of prognostic features on the final outcome in rheumatoid arthritis: a review of the literature. Semin Arthritis Rheum 1988; 17:284-292.
19. Tunn EJ, Bacon PA. Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. Br J Rheumatol 1993; 32:97-103.
20. Siegel DM. Chronic arthritis in adolescence. Adolesc Med State Art Rev 2007; 18:47-61.
21. Nell-Duxneuner V, Machold K, Stamm T, Eberl G, Heinzl H, Hoefler E et al. Autoantibody profiling in patients with very early rheumatoid arthritis - a follow-up study. Ann Rheum Dis. 2010; 69(1):169-174.
22. Tedesco A, D'Agostino D, Soriente I, Amato P, Piccoli R, Sabatini P. A new strategy for the early diagnosis of rheumatoid arthritis: a combined approach. Autoimmun Rev 2009; 8:233-237.
23. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146:797-808.
24. Vittecoq O, Pouplin S, Krzanowska K, Jouen-Beades F, Menard JF, Gayet A et al. Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients. Rheumatology (Oxford) 2003; 42: 939-946.
25. Vallbracht I, Rieber J, Oppermann M, Förger F, Siebert U, Helmke K. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor is o types in rheumatoid arthritis. Ann Rheum Dis 2004; 63:1079-1084.
26. Greiner A, Plischke H, Kellner H, Gruber R. Association of anticyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann N Y Acad Sci 2005; 1050:295-303.
27. Wolfe F, Cathey MA, Roberts FK. The latex test revised rheumatoid factor testing in 8,287 rheumatic disease patients. Arthritis Rheum 1991; 34:951-960.
28. Schellekens GA, Visser H, de Jong BAW, van den Hoogen FH, Hazes JM, Breedveld FC et al: The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43:115-163.
29. Visser H. Early diagnosis of rheumatoid arthritis. Best Pract & Res Clin Rheum 2005; 19:55-72.
30. Saraux A, Berthelot JM, Chalès G, Le Henaff C, Mary JY, Thorel JB et al. Value of laboratory tests in early prediction of rheumatoid arthritis. Arthritis Rheum 2002; 47:155-165.
31. Vittecoq O, Pouplin S, Krzanowska K, Jouen-Beades F, Menard JF, Gayet A et al. Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients. Rheumatology (Oxford) 2003; 42:939-946.
32. Procaccia S, Gasparini A, Colucci A, Lanzanova D, Bianchi M, Forcellini P et al. ELISA determined IgM, IgG and IgA rheumatoid factors in rheumatoid arthritis and in other connective tissue diseases. Clin Exp Rheumatol 1987; 5:335-342.
33. Westwood OM, Nelson PN, Hay FC. Rheumatoid factor: what's new? Rheumatology Oxford 2006; 45:379-385.
34. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value for anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006; 65:845-851.
35. Dorner T, Egerer K, Feist E, Burmester GR. Rheumatoid factor revisited. Curr Opin Rheumatol 2004; 16:246-253.
36. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2002; 3:236-243.
37. Saraux A, Berthelot JM, Devauchelle V, Bendaoud B, Chalès G, Le Henaff C et al. Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis. J Rheumatol 2004; 30:2535-2539.
38. Sauerland U, Becker H, Seide M, Schotte H, Willeke P, Schorat A et al. Clinical utility of the anti-CCP assay: experiences with 700 patients. Ann NY Acad Sci 2005; 1050:314-318.
39. Dubrous P, Gardet V, Hugard L. Value of anti-cyclic citrullinated peptides antibodies in comparison with rheumatoid factor for rheumatoid arthritis diagnosis. Pathol Biol 2005; 53:63-67.
40. Silveira IG, Burlingame RW, von Mühlen CA, Bender AL, Staub HL. Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF. Clin Rheumatol 2007; 26:1883-1889.
41. Vallbracht I, Helmke K. Additional diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor is o types in rheumatoid arthritis. Autoimmun Rev 2005; 4:389-394.
42. Solanki K, Spellerberg M, Chapman P, Moller P, O'Donnell J. Anticyclic citrullinated antibodies: complementary to IgM rheumatoid factor in the early diagnosis of rheumatoid arthritis. J N Z Med 2004; 117:1097.
43. Araki C, Hayashi N, Moriyama M, Morinobu S, Mukai M, Koshiba M et al. Usefulness of anticyclic citrullinated peptide antibodies (anti-CCP) for the diagnosis of rheumatoid arthritis. Rinsho Byori 2004; 52:966-972.
44. van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HM et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007; 56:1424-1432.
45. Quinn MA, Gough AKS, Green MJ, Devlin J, Henrsor EMA, Greenstein A et al. Anti-CCP antibodies measured at disease onset help identify soronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology 2006; 45:478-480.
46. Anjos LME, Pereira IA, d'Orsi E, Seaman A, Burlingame RW, Morato EF. A comparative study of IgG second and third generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IA third generation ELISA for the diagnosis of RA. Clin Reumatol 2009; 28:153-158.
47. Vieira LMEA, d'Orse E, Pereira IA, Morato EF, Burlingame R. Rheumatoid arthritis diagnosis: a comparative study of second and third generation anti-cyclic citrullinated peptide (CCP) antibody ELISAs. INOVA Newsletter 2007; 2:8-9.
48. Santiago M, Baron M, Miyachi K, Fritzler MJ, Abu-Hakima M, Leclercq et al. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol 2008; 27:77-83.
49. Wu R, Shovman O, Zhang Y, Gilburd B, Zandman-Goddard G, Shoenfeld Y (2007) Increased prevalence of anti-third generation cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis and CREST syndrome. Clin Rev Allergy Immunol 2007; 32:47-56.
50. Caro-Oleas JL, Fernandez-Suarez A, Reneses-Casteros S, Porrino C, Nunes-Roldan A, Wichmann-Schlipf I. Diagnostic usefulness of a third generation anti-cyclic citrulline antibody test in patients with recent-onset polyarthritis. Clin Chem Lab Med 2007; 45:1396-1401.
51. Lutteri L, Malaise M, Chapelle JP. Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis. Clin Chim Acta 2007; 386:76-81.
52. Szekanecz Z, Burlingame R. The INOVA CCP 3.1 IgA/IgG ELISA represents significant improvement in the laboratory diagnosis of rheumatoid arthritis. INOVA Newsletter 2007; 2:6-7.
53. Bizzaro N, Tonutti E, Tozzoli R, Villalta D. Analytical and Diagnostic Characteristics of 11 2nd- and 3rd-Generation Immunoenzymatic Methods for the Detection of Antibodies to Citrullinated Proteins. Clin Chem 2007; 53:1527-1533.
54. Lee DM, Phillps R, Hagan EM, Chibnik LB, Costenbader KH, Schur PH. Quantifying anti-cyclic citrullinated peptide titres: clinical utility and association with tobacco exposure in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68:201-208.
55. Papadooulos NG, Tsiasousis GZ, avlitou-Tsioontsi A, Giannakon A, Galanopoulou VK. Does the presence of anti-CC autoantivodies and their serum levels influence the severity and activity in rheumatoid arthritis patients? Cli Rev Allergy Immunol 2008; 34:11-15.
56. Vossenaar ER, Després N, Lapointe E, van de Heijden A, Lora M, Senshu T et al. Rheumatoid arthritis specific anti-Sa antibodies target citrulliated vimentin. Arthritis Res Ther 2004; 6:142-150.
57. Innala L, Kokkonen H, Ericsson C, Jidell E, Berglin E, Rantapää- Dahlqvist S. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008; 35:1002-1008.